AZ Relinquishes Rights to Opioid Constipation Treatment

AstraZeneca announced last week its intention to hand over rights to Moventig — a treatment for opioid-induced constipation — to Kyowa subsidiary ProStrakan Group for $70 million.

Under the agreement, ProStrakan will pay AstraZeneca tiered double-digit royalties on sales and milestones for the product, which is known as Movantik in the U.S.